JVC 001

Drug Profile

JVC 001

Alternative Names: Measles-mumps-and-rubella-virus-vaccine-Daiichi; MMR-vaccine-Daiichi-Sankyo; VN-0102

Latest Information Update: 09 Dec 2015

Price : $50

At a glance

  • Originator Japan Vaccine
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Measles; Mumps; Rubella

Most Recent Events

  • 31 Oct 2015 Phase-I/II clinical trials in Measles (Prevention) in Japan (Parenteral)
  • 31 Oct 2015 Phase-I/II clinical trials in Rubella (Prevention) in Japan (Parenteral)
  • 31 Oct 2015 Phase-I/II clinical trials in Mumps (Prevention) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top